Cholestasis
Drug research and approvals for cholestasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 58 studies of cholestasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 4 approved and 4 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 58
- Trials authorized in Canada: 6
- FDA orphan approvals: 4
- EU medicines: 3
- Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisNCT07841977 · Phase 2 · Gilead Sciences · starts Oct 1, 2026
- The Dirty Nappy StudyNCT07697872 · Not reported · Birmingham Women's and Children's NHS Foundation Trust · starts Apr 1, 2025
- Vitamin D2 vs Vitamin D2 Plus Calcitriol in Cholestatic Children With Vitamin D DeficiencyNCT07670611 · Phase 4 · Chulalongkorn University · starts Apr 28, 2026
- Austrian PBC RegistryNCT07598669 · Not reported · Medical University of Vienna · starts Mar 18, 2026
- A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic…NCT07588880 · Not reported · Ipsen · starts Apr 16, 2026
- A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving…NCT07585097 · Not reported · Ipsen · starts Jul 10, 2026
- Prealbumin and IGF-1 Levels in Pediatric Chronic Cholestasis With Severe Malnutrition After Nutrition TherapyNCT07569003 · Not applicable · Universitas Indonesia · starts Apr 6, 2026
- Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During PregnancyNCT07556913 · Not reported · Ipsen · starts Jul 29, 2026
- Biochemical Response and Clinical Outcomes in Patients With PBCNCT07449793 · Not reported · RenJi Hospital · starts Feb 1, 2026
Approved 2
- Fish oil triglyceridesSupplement
- TocofersolanNutritional support
Phase 3 4
- Soybean oil
- LinerixibatIleal bile acid transporter inhibitor
- Icosapent
- Fish oilSupplement
Phase 2 3
- UrsodiolBile acid receptor FXR agonist
- Fenofibric acidPeroxisome proliferator-activated receptor alpha agonist
- OdevixibatIleal bile acid transporter inhibitor
Phase 1 or earlier 1
- Obeticholic acidBile acid receptor FXR agonist
How its trials ended
230 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 47 whose ending is known, 36% met their primary endpoint, 4% missed it and 60% stopped early.
- Completed, result not reported7934%
- Ongoing5725%
- Status unknown4720%
- Stopped: other or unclear198%
- Met its primary endpoint177%
- Stopped: enrollment or feasibility73%
- Missed its primary endpoint21%
- Stopped: safety1<1%
- Stopped: funding1<1%
| Feb 14, 2020 | A long-term safety study of maralixibat, an apical sodium dependent bile acid transporter inhibitor (ASBTI), in the treatment of cholestatic liver disease in…Maralixibat (LUM001, SHP625) | Mirum Pharmaceuticals | Closed |
| Jan 2, 2020 | An open-label extension study to evaluate the long-term safety and efficacy of maralixibat in the treatment of subjects with progressive familial intrahepatic…Maralixibat | Mirum Pharmaceuticals | Closed |
| Aug 22, 2019 | Randomized double-blind placebo-controlled phase 3 study to evaluate the efficacy and safety of maralixibat in the treatment of subjects with progressive…Maralixibat | Mirum Pharmaceuticals | Closed |
| Sep 7, 2018 | An open-label extension study to evaluate long-term efficacy and safety of A4250 in children with progressive familial intrahepatic cholestasis types 1 and 2…Odevixibat (A4250) | Albireo Pharma | Closed |
| Mar 21, 2018 | A double-blind, randomized, placebo-controlled, phase 3 study to demonstrate efficacy and safety of A4250 in children with progressive familial intrahepatic…A4250 | Albireo Pharma | Closed |
| Feb 6, 2014 | Open label study of the efficacy and long term safety of LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTI), in the treatment of…Maralixibat (LUM001) | Lumena Pharmaceuticals Inc | Closed |
| Jul 24, 2024 | LivmarliTreatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC) | Mirum Pharmaceuticals, Inc. | Approved |
| Mar 13, 2024 | LivmarliTreatment of cholestatic pruritus in patients 5 years of age and older with progressive familial intrahepatic cholestasis (PFIC) | Mirum Pharmaceuticals, Inc. | Approved |
| Jul 20, 2021 | BylvayTreatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use:… | Ipsen Biopharmaceuticals, Inc. | Approved |
| Jul 27, 2018 | OmegavenOmegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC) | Fresenius Kabi USA, LLC | Approved |
| Nov 18, 2024 | Modified human ATP binding cassette subfamily B member 4…Treatment of progressive familial intrahepatic cholestasis type 3 (PFIC3) | Shenzhen Shenxin Biotechnology Co., Ltd. | Designated |
| Jul 29, 2024 | Modified human ATP binding cassette subfamily B member 11…Treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2) | Shenzhen Shenxin Biotechnology Co., Ltd. | Designated |
| Oct 22, 2020 | 3alpha,6beta,7beta,12alpha-tetrahydroxy-5beta-cholan-24-oic…Treatment of progressive familial intrahepatic cholestasis | Qing Bile Therapeutics, Inc. | Designated |
| Feb 10, 1994 | Choline chlorideTreatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term… | Protara Therapeutics, Inc. | Designated |
| Dec 9, 2022 | LivmarliMaralixibat chloride · orphan | Mirum Pharmaceuticals International B.V. | EMA ↗ |
| Jul 16, 2021 | BylvayOdevixibat · orphan | Ipsen Pharma | EMA ↗ |
| Jul 23, 2009 | VedropTocofersolan | Recordati Rare Diseases | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA